AnakinraToxidermia follwing off-label treatment: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1751卷 / 1期

关键词：

D O I：

10.1007/s40278-019-61168-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：35 / 35

相关论文

共 50 条

[21] Multiple drugsInefficacy following off-label treatment: case report
Reactions Weekly, 2022, 1887 (1) : 477 - 477
[22] MizoribineFanconi syndrome following off-label treatment: case report
Reactions Weekly, 2021, 1838 (1) : 341 - 341
[23] IobenguaneAnorexia and nausea following off-label treatment: case report
Reactions Weekly, 2020, 1810 (1) : 119 - 119
[24] OsimertinibVarious toxicities following off-label treatment: case report
Reactions Weekly, 2018, 1724 (1) : 285 - 285
[25] Capecitabine/lapatinibMucositis following off-label treatment: case report
Reactions Weekly, 2019, 1781 (1) : 96 - 96
[26] TrametinibAcquired drug resistance with off-label treatment: case report
Reactions Weekly, 2019, 1774 (1) : 298 - 298
[27] AmantadineUrinary retention following off-label treatment: case report
Reactions Weekly, 2021, 1866 (1) : 33 - 33
[28] Dacarbazine/gemcitabineInefficacy following off-label treatment: case report
Reactions Weekly, 2021, 1872 (1) : 160 - 160
[29] TucidinostatThrombocytopenia while receiving off-label treatment : case report
Reactions Weekly, 2020, 1824 (1) : 267 - 267
[30] PosaconazoleHepatotoxicity and off-label use: case report
Reactions Weekly, 2024, 2021 (1) : 447 - 447

← 1 2 3 4 5 →